

Aug 19, 2026

Notice Regarding Offer of Refunds to 340B Covered Entities

Genentech, Inc. ("Genentech") has recently recalculated 340B Ceiling Prices for the covered outpatient drugs listed below for the following time period(s): 3Q2023.

As a result of revised pricing data submitted to the Centers for Medicare & Medicaid Services (CMS), Genentech has determined that, pursuant to 42 U.S.C. § 256b(d)(1)(B)(ii) and 42 C.F.R. § 10.11(b)(4), a refund is or may be due to eligible 340B Covered Entities that purchased these products during the affected periods.

Products Subject to 340B Ceiling Price Recalculation

Time Period	Product Description	NDC-11
3Q2023	Lucentis 0.5MG/0.5ML PFS	50242008003
3Q2023	Lucentis 0.3mg (0.5mL) Vial	50242008202
3Q2023	Lucentis 0.3mg (0.5mL) Vial	50242008203

Refund Process Guidelines

Genentech will process refund payments based on the aggregate total refund amount owed to a 340B Covered Entity across all applicable NDCs for the specified period:

1. Aggregated Refunds Equal to or In Excess of \$75

- Automatic Processing: If your aggregate refund amount across all applicable NDCs and time periods is equal to or exceeds \$75.00, Genentech (or its designated vendor) will issue payment directly to your Covered Entity of record.

2. Aggregated Refunds Below \$75

- Proactive Request Required: For 340B Covered Entities whose aggregate refund amount across all applicable NDCs and time periods is less than \$75, **refunds will not be issued automatically**. Instead, entities must proactively request a refund by following the instructions below:

1. Initiate Contact:

- Send an email to Genentech_340B_Refund_Ops@gene.com with the subject line:
340B Refund Request - [Insert Covered Entity 340B ID] - 3Q2023 Lucentis

2. Provide Required Details: Include the following information in your request:

- Covered Entity Name and 340B ID
- Contact Person Name, Title, and Email Address
- Affected Product Name(s) and 11-Digit NDC(s)

- Eligible covered entities have one (1) year from the HRSA website posting date of this notice to contact Genentech and request a credit or refund.
3. Verification & Issuance: Genentech will review your submission, verify eligibility against historical sales data, and contact you with instructions on how the refund will be remitted.

Transparency & Questions

Genentech has requested that the Health Resources and Services Administration (HRSA) post this notice on its public website to ensure full transparency to all 340B Covered Entities regarding these ceiling price recalculations.

If you have questions regarding this notice or wish to inquire about refund eligibility, please contact Genentech at Genentech_340B_Refund_Ops@gene.com.